High dose imatinib (STI571, Gleevec®) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC):: Follow-up of the phase II studies.

被引：0
|
作者：
Talpaz, M
Goldman, JM
Sawyers, CL
Hochhaus, A
Silver, RT
Smith, BD
So, C
Gathmann, I
Druker, BJ
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3369
引用
收藏
页码：905A / 906A
页数：2
相关论文
共 50 条
  • [31] Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in long-term outcome for patients (Pts) with chronic phase (CP) chronic myeloid leukemia (CML)
    Alvarado, Yesid
    Kantarjian, Hagop
    Faderl, Stefan
    Burger, Jan
    Borthakur, Gautam
    O'Brien, Susan
    Wierda, William
    Garcia-Manero, Guillermo
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 573A - 573A
  • [32] A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
    Giles, F. J.
    le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Zheng, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure
    Shan, J.
    O'Brien, S. M.
    Garcia-Manero, G.
    Faderl, S.
    Ravandi, F.
    Jabbour, E.
    Cortes, J. E.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up.
    Aoki, E.
    Kantarjian, H.
    O'Brien, S.
    Talpaz, M.
    Giles, F.
    Garcia-Manero, G.
    Wierda, W.
    Verstovsek, S.
    Jones, D.
    Luthra, R.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 345S - 345S
  • [36] Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
    Pepe, Sara
    Scalzulli, Emilia
    Colafigli, Gioia
    Di Prima, Alessio
    Mancini, Marco
    Diverio, Daniela
    Latagliata, Roberto
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2261 - 2266
  • [37] Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
    Gambacorti-Passerini, C.
    Cortes, J. E.
    Kim, D.
    Kantarjian, H.
    Khattry, N.
    Lipton, J. H.
    Powell, C.
    Harris, P.
    Countouriotis, A. M.
    Brummendorf, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    Larson, R. A.
    Kim, D.
    Rosti, G.
    Stenke, L.
    Pasquini, R.
    Hoenekopp, A.
    Blakesley, R. E.
    Gallagher, N. J.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [40] Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up
    Leber, Brian
    Cervantes, Francisco
    Spector, Nelson
    Lipton, Jeffrey H.
    Etienne, Gabriel
    Pasquini, Ricardo
    Clementino, Nelma Christina
    Guerci-Bresler, Agnes
    Forrest, Donna
    Schwarer, Anthony P.
    Acharya, Sandip
    Collins, LaTonya
    Szczudlo, Tomasz
    Hughes, Timothy P.
    BLOOD, 2013, 122 (21)
12345